Article

Transvitreal optic neurotomy improves visual acuity in recent-onset NAION

Transvitreal optic neurotomy (TON) improves the visual acuity and visual fields in patients with nonarteritic anterior ischemic optic neuropathy (NAION) of recent onset, reported Gholam Peyman, MD, at the American Academy of Ophthalmology annual meeting.

Transvitreal optic neurotomy (TON) improves the visual acuity and visual fields inpatients with nonarteritic anterior ischemic optic neuropathy (NAION) of recent onset, reportedGholam Peyman, MD, at the American Academy of Ophthalmology annual meeting.

Sixteen patients were included in this masked clinical trial. Eight patients were randomized toundergo TON and eight to observation. The TON procedure included pars plana vitrectomy. An MVR bladewas used to cut through the pars plana and the margin of the optic nerve was incised. Patients wereexamined at 1, 3, 7, and 28 days and then monthly to 6 months postoperatively, Dr. Peyman explained.He is from the Tulane Health Science Center, New Orleans.

The results showed that in the patients who underwent TON, the best-corrected visual acuity was 2.03± 0.9 compared with 1.11 ± 0.37 for the control patients. The mean visual acuity improvementwas greater in the surgical group than in the controls at 3 (0.8 ± 0.49 compared with 0.24± 0.45, respectively; p = 0.03) and 6 (1.04 ± 0.83 compared with 0.24 ± 0.45,respectively; p = 0.03) months postoperatively. Seventy-five percent of the surgical patientshad an increase in visual acuity compared with 25% of controls (p = 0.04). The visual fieldsimproved significantly (p = 0.01) in 75% of the surgical patients.

"TON may play a role in the treatment of NAION," Dr. Peyman concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.